Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios

Journal of Clinical Lipidology

Volumn 5, Issue 3, 2011, Pages 159-165

  Vodnala, Deepthi ^a   Bard, Robert L ^a   Krishnan, Sangeetha M ^a   Jackson, Elizabeth A ^a   Rubenfire, Melvyn ^a   Brook, Robert D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apolipoproteins; Cardiovascular risk; Lipid ratios; Lipoproteins; Prevention

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ADULT TREATMENT PANEL; AGED; ALGORITHM; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK; TREATMENT RESPONSE;

ADULT; AGED; ALGORITHMS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79956271699     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.02.004     Document Type: Conference Paper

References (17)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation 106 2002 3143 3421
2. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
3. M.J. McQueen, S. Hawken, and X. Wang Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case control study Lancet 372 2008 224 233 (Pubitemid 351978112)
4. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
5. J. De Graaf, P. Couture, and A. Sniderman A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias Nat Clin Pract Endocrinol Metab 4 2008 608 618
6. J.J.P. Kastelein, W.A. van der Steeg, and I. Holme Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
7. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, and E.B. Rimm Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 2005 3375 3383 (Pubitemid 43739551)
8. E.A. Stein, A. Sniderman, and P. Laskarzewski Assessment of reaching goal in patient with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 96 suppl 2005 36K 43K (Pubitemid 41598111)
9. A.S. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.-P. Despres, and B. Lamarch Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177 (Pubitemid 36561379)
10. R.D. Brook, H. Doshi, R.L. Bard, and M. Rubenfire Potential effect of an apoprotein B-based algorithm on management of new patients with hypertriglyceridemia referred to a specialty lipid clinic Clin Cardiol 32 2009 251 255
11. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
12. Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths Lancet 340 2007 1829 1839
13. C.J. Packard, I. Ford, and M. Robertson Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation 112 2005 3058 3065 (Pubitemid 43113436)
14. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051 (Pubitemid 34014055)
15. Cholesterol Treatment Trialists (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials Lancet 376 2010 1670 1681
16. J.O. Mudd, B.A. Borlaug, and P.V. Johnston Beyond low-density lipoprotein cholesterol. Defining the role of low-density lipoprotein heterogeneity in coronary artery disease J Am Coll Cardiol 50 2007 1735 1741 (Pubitemid 47600586)
17. A.D. Sniderman, K. Williams, M.J. McQueen, and C.D. Furberg When is equal not equal? J Clin Lipidol 4 2010 83 88